{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:50:31Z","timestamp":1789901431480,"version":"4.0.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s13402-017-0314-z","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T09:53:52Z","timestamp":1486115632000},"page":"167-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells"],"prefix":"10.1007","volume":"40","author":[{"given":"Maria Saveria","family":"Gilardini Montani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Granato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Del Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Merendino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"D\u2019Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Faggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Cirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,3]]},"reference":[{"key":"314_CR1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"R Siegel","year":"2011","unstructured":"R. Siegel, E. Ward, O. Brawley, A. Jemal, Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212\u2013236 (2011)","journal-title":"CA Cancer J Clin"},{"key":"314_CR2","doi-asserted-by":"crossref","unstructured":"M. Giulietti, G. Occhipinti, G. Principato, F. Piva, Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development. Cell Oncol 39, 379\u2013388 (2016)","DOI":"10.1007\/s13402-016-0283-7"},{"key":"314_CR3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000065068","volume":"62","author":"X Shi","year":"2002","unstructured":"X. Shi, S. Liu, J. Kleeff, H. Friess, M.W. Buchler, Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62, 354\u2013362 (2002)","journal-title":"Oncology"},{"key":"314_CR4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2009.89","volume":"6","author":"HH Wong","year":"2009","unstructured":"H.H. Wong, N.R. Lemoine, Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6, 412\u2013422 (2009)","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"314_CR5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-230X(02)86002-X","volume":"86","author":"H Lehrmann","year":"2002","unstructured":"H. Lehrmann, L.L. Pritchard, A. Harel-Bellan, Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86, 41\u201365 (2002)","journal-title":"Adv Cancer Res"},{"key":"314_CR6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/15216540500090629","volume":"57","author":"C Das","year":"2005","unstructured":"C. Das, T.K. Kundu, Transcriptional regulation by the acetylation of nonhistone proteins in humans -- a new target for therapeutics. IUBMB Life 57, 137\u2013149 (2005)","journal-title":"IUBMB Life"},{"key":"314_CR7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biocel.2008.08.027","volume":"41","author":"S Spange","year":"2009","unstructured":"S. Spange, T. Wagner, T. Heinzel, O.H. Kramer, Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41, 185\u2013198 (2009)","journal-title":"Int J Biochem Cell Biol"},{"key":"314_CR8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg962","volume":"3","author":"PA Jones","year":"2002","unstructured":"P.A. Jones, S.B. Baylin, The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415\u2013428 (2002)","journal-title":"Nat Rev Genet"},{"key":"314_CR9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"S. Minucci, P.G. Pelicci, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38\u201351 (2006)","journal-title":"Nat Rev Cancer"},{"key":"314_CR10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.coph.2006.03.010","volume":"6","author":"N Carey","year":"2006","unstructured":"N. Carey, N.B. La Thangue, Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol 6, 369\u2013375 (2006)","journal-title":"Curr Opin Pharmacol"},{"key":"314_CR11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","volume":"107","author":"PA Marks","year":"2009","unstructured":"P.A. Marks, W.S. Xu, Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107, 600\u2013608 (2009)","journal-title":"J Cell Biochem"},{"key":"314_CR12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13402-015-0233-9","volume":"38","author":"C Cortes","year":"2015","unstructured":"C. Cortes, S.C. Kozma, A. Tauler, S. Ambrosio, MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells. Cell Oncol 38, 341\u2013352 (2015)","journal-title":"Cell Oncol"},{"key":"314_CR13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s13402-015-0255-3","volume":"39","author":"B Jang","year":"2016","unstructured":"B. Jang, J.A. Shin, Y.S. Kim, J.Y. Kim, H.K. Yi, I.S. Park, N.P. Cho, S.D. Cho, Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells. Cell Oncol 39, 79\u201387 (2016)","journal-title":"Cell Oncol"},{"key":"314_CR14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2174\/1871520615666150520093040","volume":"15","author":"Z Chen","year":"2015","unstructured":"Z. Chen, Y. Yang, B. Liu, B. Wang, M. Sun, L. Zhang, B. Chen, H. You, M. Zhou, Promotion of metastasis-associated Gene expression in survived PANC-1 cells following trichostatin a treatment. Anti Cancer Agents Med Chem 15, 1317\u20131325 (2015)","journal-title":"Anti Cancer Agents Med Chem"},{"key":"314_CR15","first-page":"293","volume":"22","author":"J Jones","year":"2008","unstructured":"J. Jones, W. Bentas, R.A. Blaheta, J. Makarevic, L. Hudak, S. Wedel, M. Probst, D. Jonas, E. Juengel, Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Int J Mol Med 22, 293\u2013299 (2008)","journal-title":"Int J Mol Med"},{"key":"314_CR16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1476-4598-9-80","volume":"9","author":"S Schuler","year":"2010","unstructured":"S. Schuler, P. Fritsche, S. Diersch, A. Arlt, R.M. Schmid, D. Saur, G. Schneider, HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer 9, 80 (2010)","journal-title":"Mol Cancer"},{"key":"314_CR17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"J.E. Bolden, M.J. Peart, R.W. Johnstone, Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5, 769\u2013784 (2006)","journal-title":"Nat Rev Drug Discov"},{"key":"314_CR18","doi-asserted-by":"crossref","first-page":"315939","DOI":"10.1155\/2011\/315939","volume":"2011","author":"M Ouaissi","year":"2011","unstructured":"M. Ouaissi, U. Giger, I. Sielezneff, N. Pirro, B. Sastre, A. Ouaissi, Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J Biomed Biotechnol 2011, 315939 (2011)","journal-title":"J Biomed Biotechnol"},{"key":"314_CR19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1242\/jcs.031682","volume":"122","author":"JK Brunelle","year":"2009","unstructured":"J.K. Brunelle, A. Letai, Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122, 437\u2013441 (2009)","journal-title":"J Cell Sci"},{"key":"314_CR20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","volume":"8","author":"G Pistritto","year":"2016","unstructured":"G. Pistritto, D. Trisciuoglio, C. Ceci, A. Garufi, G. D'Orazi, Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY) 8, 603\u2013619 (2016)","journal-title":"Aging (Albany NY)"},{"key":"314_CR21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bbamcr.2005.07.003","volume":"1745","author":"F Natoni","year":"2005","unstructured":"F. Natoni, L. Diolordi, C. Santoni, M.S. Gilardini Montani, Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta 1745, 318\u2013329 (2005)","journal-title":"Biochim Biophys Acta"},{"key":"314_CR22","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","volume":"22","author":"OH Kramer","year":"2003","unstructured":"O.H. Kramer, P. Zhu, H.P. Ostendorff, M. Golebiewski, J. Tiefenbach, M.A. Peters, B. Brill, B. Groner, I. Bach, T. Heinzel, M. Gottlicher, The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22, 3411\u20133420 (2003)","journal-title":"EMBO J"},{"key":"314_CR23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1210\/jc.2004-1355","volume":"90","author":"MG Catalano","year":"2005","unstructured":"M.G. Catalano, N. Fortunati, M. Pugliese, L. Costantino, R. Poli, O. Bosco, G. Boccuzzi, Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90, 1383\u20131389 (2005)","journal-title":"J Clin Endocrinol Metab"},{"key":"314_CR24","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"M. Gottlicher, S. Minucci, P. Zhu, O.H. Kramer, A. Schimpf, S. Giavara, J.P. Sleeman, F. Lo Coco, C. Nervi, P.G. Pelicci, T. Heinzel, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20, 6969\u20136978 (2001)","journal-title":"EMBO J"},{"key":"314_CR25","doi-asserted-by":"crossref","first-page":"11083","DOI":"10.1021\/bi0494471","volume":"43","author":"BE Schultz","year":"2004","unstructured":"B.E. Schultz, S. Misialek, J. Wu, J. Tang, M.T. Conn, R. Tahilramani, L. Wong, Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. Biochemistry 43, 11083\u201311091 (2004)","journal-title":"Biochemistry"},{"key":"314_CR26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1756-9966-32-95","volume":"32","author":"MS Gilardini Montani","year":"2013","unstructured":"M.S. Gilardini Montani, A. Prodosmo, V. Stagni, D. Merli, L. Monteonofrio, V. Gatti, M.P. Gentileschi, D. Barila, S. Soddu, ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res 32, 95 (2013)","journal-title":"J Exp Clin Cancer Res"},{"key":"314_CR27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2015.07.006","volume":"366","author":"M Granato","year":"2015","unstructured":"M. Granato, B. Chiozzi, M.R. Filardi, L.V. Lotti, L. Di Renzo, A. Faggioni, M. Cirone, Tyrosine kinase inhibitor tyrphostin AG490 triggers both apoptosis and autophagy by reducing HSF1 and mcl-1 in PEL cells. Cancer Lett 366, 191\u2013197 (2015)","journal-title":"Cancer Lett"},{"key":"314_CR28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jcb.24709","volume":"115","author":"LA Gillies","year":"2014","unstructured":"L.A. Gillies, T. Kuwana, Apoptosis regulation at the mitochondrial outer membrane. J Cell Biochem 115, 632\u2013640 (2014)","journal-title":"J Cell Biochem"},{"key":"314_CR29","doi-asserted-by":"crossref","first-page":"10153","DOI":"10.1074\/jbc.M510349200","volume":"281","author":"J Han","year":"2006","unstructured":"J. Han, L.A. Goldstein, B.R. Gastman, H. Rabinowich, Interrelated roles for mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 281, 10153\u201310163 (2006)","journal-title":"J Biol Chem"},{"key":"314_CR30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1083\/jcb.144.5.903","volume":"144","author":"GJ Griffiths","year":"1999","unstructured":"G.J. Griffiths, L. Dubrez, C.P. Morgan, N.A. Jones, J. Whitehouse, B.M. Corfe, C. Dive, J.A. Hickman, Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 144, 903\u2013914 (1999)","journal-title":"J Cell Biol"},{"key":"314_CR31","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10495-007-0749-1","volume":"12","author":"L Lalier","year":"2007","unstructured":"L. Lalier, P.F. Cartron, P. Juin, S. Nedelkina, S. Manon, B. Bechinger, F.M. Vallette, Bax activation and mitochondrial insertion during apoptosis. Apoptosis 12, 887\u2013896 (2007)","journal-title":"Apoptosis"},{"key":"314_CR32","doi-asserted-by":"crossref","first-page":"15814","DOI":"10.18632\/oncotarget.4538","volume":"6","author":"I Ischenko","year":"2015","unstructured":"I. Ischenko, O. Petrenko, M.J. Hayman, A MEK\/PI3K\/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. Oncotarget 6, 15814\u201315827 (2015)","journal-title":"Oncotarget"},{"key":"314_CR33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(00)80308-1","volume":"3","author":"R Sears","year":"1999","unstructured":"R. Sears, G. Leone, J. DeGregori, J.R. Nevins, Ras enhances Myc protein stability. Mol Cell 3, 169\u2013179 (1999)","journal-title":"Mol Cell"},{"key":"314_CR34","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/onc.2015.216","volume":"35","author":"E Hessmann","year":"2016","unstructured":"E. Hessmann, G. Schneider, V. Ellenrieder, J.T. Siveke, MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. Oncogene 35, 1609\u20131618 (2016)","journal-title":"Oncogene"},{"key":"314_CR35","unstructured":"N. Angela, V. Carafa, M. Conte, F.P. Tambaro, C. Abbondanza, J.H. Martens, M. Nees, R. Benedetti, I. Pallavicini, S. Minucci, G. Garcia-Manero, F. Iovino, G. Lania, C. Ingenito, V. Belsito Petrizzi, H.G. Stunnenberg and L. Altucci, c-Myc modulation & acetylation is a key HDAC inhibitor target in cancer. Clin Cancer Res (2016)"},{"key":"314_CR36","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s004280100474","volume":"439","author":"PS Moore","year":"2001","unstructured":"P.S. Moore, B. Sipos, S. Orlandini, C. Sorio, F.X. Real, N.R. Lemoine, T. Gress, C. Bassi, G. Kloppel, H. Kalthoff, H. Ungefroren, M. Lohr, A. Scarpa, Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4\/Smad4. Virchows Arch 439, 798\u2013802 (2001)","journal-title":"Virchows Arch"},{"key":"314_CR37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","volume":"9","author":"R Brosh","year":"2009","unstructured":"R. Brosh, V. Rotter, When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9, 701\u2013713 (2009)","journal-title":"Nat Rev Cancer"},{"key":"314_CR38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PA Muller","year":"2013","unstructured":"P.A. Muller, K.H. Vousden, p53 mutations in cancer. Nat Cell Biol 15, 2\u20138 (2013)","journal-title":"Nat Cell Biol"},{"key":"314_CR39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tips.2010.11.004","volume":"32","author":"CJ Brown","year":"2011","unstructured":"C.J. Brown, C.F. Cheok, C.S. Verma, D.P. Lane, Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32, 53\u201362 (2011)","journal-title":"Trends Pharmacol Sci"},{"key":"314_CR40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbamcr.2014.10.003","volume":"1853","author":"C Fiorini","year":"2015","unstructured":"C. Fiorini, M. Cordani, C. Padroni, G. Blandino, S. Di Agostino, M. Donadelli, Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta 1853, 89\u2013100 (2015)","journal-title":"Biochim Biophys Acta"},{"key":"314_CR41","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1158\/1541-7786.MCR-05-0121","volume":"3","author":"CM Aliouat-Denis","year":"2005","unstructured":"C.M. Aliouat-Denis, N. Dendouga, I. Van den Wyngaert, H. Goehlmann, U. Steller, I. van de Weyer, N. Van Slycken, L. Andries, S. Kass, W. Luyten, M. Janicot, J.E. Vialard, p53-independent regulation of p21Waf1\/Cip1 expression and senescence by Chk2. Mol Cancer Res 3, 627\u2013634 (2005)","journal-title":"Mol Cancer Res"},{"key":"314_CR42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1535-6108(03)00244-7","volume":"4","author":"JR Jeffers","year":"2003","unstructured":"J.R. Jeffers, E. Parganas, Y. Lee, C. Yang, J. Wang, J. Brennan, K.H. MacLean, J. Han, T. Chittenden, J.N. Ihle, P.J. McKinnon, J.L. Cleveland, G.P. Zambetti, Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321\u2013328 (2003)","journal-title":"Cancer Cell"},{"key":"314_CR43","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tcb.2007.07.009","volume":"17","author":"R Scherz-Shouval","year":"2007","unstructured":"R. Scherz-Shouval, Z. Elazar, ROS, mitochondria and the regulation of autophagy. Trends Cell Biol 17, 422\u2013427 (2007)","journal-title":"Trends Cell Biol"},{"key":"314_CR44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1073\/pnas.0408732102","volume":"102","author":"JS Ungerstedt","year":"2005","unstructured":"J.S. Ungerstedt, Y. Sowa, W.S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, P.A. Marks, Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102, 673\u2013678 (2005)","journal-title":"Proc Natl Acad Sci U S A"},{"key":"314_CR45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbamcr.2014.12.016","volume":"1853","author":"C Fiorini","year":"2015","unstructured":"C. Fiorini, M. Cordani, G. Gotte, D. Picone, M. Donadelli, Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt\/mTOR pathway in a ROS-dependent manner. Biochim Biophys Acta 1853, 549\u2013560 (2015)","journal-title":"Biochim Biophys Acta"},{"key":"314_CR46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.tibs.2010.07.007","volume":"36","author":"R Scherz-Shouval","year":"2011","unstructured":"R. Scherz-Shouval, Z. Elazar, Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci 36, 30\u201338 (2011)","journal-title":"Trends Biochem Sci"},{"key":"314_CR47","doi-asserted-by":"crossref","unstructured":"D.J. Klionsky, K. Abdelmohsen, A. Abe, et al., Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1\u2013222 (2016)","DOI":"10.1080\/15548627.2015.1100356"},{"key":"314_CR48","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2010-04-278507","volume":"116","author":"D McConkey","year":"2010","unstructured":"D. McConkey, Proteasome and HDAC: who's zooming who? Blood 116, 308\u2013309 (2010)","journal-title":"Blood"},{"key":"314_CR49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031732","volume":"7","author":"M Cirone","year":"2012","unstructured":"M. Cirone, L. Di Renzo, L.V. Lotti, V. Conte, P. Trivedi, R. Santarelli, R. Gonnella, L. Frati, A. Faggioni, Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One 7, e31732 (2012)","journal-title":"PLoS One"},{"key":"314_CR50","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1021\/pr050154j","volume":"4","author":"D Cecconi","year":"2005","unstructured":"D. Cecconi, M. Donadelli, A. Scarpa, A. Milli, M. Palmieri, M. Hamdan, L.B. Areces, J. Rappsilber, P.G. Righetti, Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin a. J Proteome Res 4, 1909\u20131916 (2005)","journal-title":"J Proteome Res"},{"key":"314_CR51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2012.06.003","volume":"325","author":"AR Goloudina","year":"2012","unstructured":"A.R. Goloudina, O.N. Demidov, C. Garrido, Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett 325, 117\u2013124 (2012)","journal-title":"Cancer Lett"},{"key":"314_CR52","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.263","volume":"4","author":"M Granato","year":"2013","unstructured":"M. Granato, V. Lacconi, M. Peddis, L.V. Lotti, L. Di Renzo, R. Gonnella, R. Santarelli, P. Trivedi, L. Frati, G. D'Orazi, A. Faggioni, M. Cirone, HSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma. Cell Death Dis 4, e730 (2013)","journal-title":"Cell Death Dis"},{"key":"314_CR53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"A.C. West, R.W. Johnstone, New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124, 30\u201339 (2014)","journal-title":"J Clin Invest"},{"key":"314_CR54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"K.J. Falkenberg, R.W. Johnstone, Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13, 673\u2013691 (2014)","journal-title":"Nat Rev Drug Discov"},{"key":"314_CR55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","volume":"121","author":"J Roche","year":"2016","unstructured":"J. Roche, P. Bertrand, Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem 121, 451\u2013483 (2016)","journal-title":"Eur J Med Chem"},{"key":"314_CR56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"C.V. Dang, MYC on the path to cancer. Cell 149, 22\u201335 (2012)","journal-title":"Cell"},{"key":"314_CR57","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fonc.2015.00288","volume":"5","author":"A Parrales","year":"2015","unstructured":"A. Parrales, T. Iwakuma, Targeting oncogenic mutant p53 for cancer therapy. Front Oncol 5, 288 (2015)","journal-title":"Front Oncol"},{"key":"314_CR58","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/sj.onc.1210294","volume":"26","author":"L Weisz","year":"2007","unstructured":"L. Weisz, M. Oren, V. Rotter, Transcription regulation by mutant p53. Oncogene 26, 2202\u20132211 (2007)","journal-title":"Oncogene"},{"key":"314_CR59","doi-asserted-by":"crossref","unstructured":"G. Bougeard, R. Sesboue, S. Baert-Desurmont, S. Vasseur, C. Martin, J. Tinat, L. Brugieres, A. Chompret, B.B. de Paillerets, D. Stoppa-Lyonnet, C. Bonaiti-Pellie, T. Frebourg, L.F.S.w.g. French, Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45, 535\u2013538 (2008)","DOI":"10.1136\/jmg.2008.057570"},{"key":"314_CR60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/humu.22254","volume":"34","author":"Y Zerdoumi","year":"2013","unstructured":"Y. Zerdoumi, J. Aury-Landas, C. Bonaiti-Pellie, C. Derambure, R. Sesboue, M. Renaux-Petel, T. Frebourg, G. Bougeard, J.M. Flaman, Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients. Hum Mutat 34, 453\u2013461 (2013)","journal-title":"Hum Mutat"},{"key":"314_CR61","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.217","volume":"5","author":"A Garufi","year":"2014","unstructured":"A. Garufi, D. Pucci, V. D'Orazi, M. Cirone, G. Bossi, M.L. Avantaggiati, G. D'Orazi, Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell Death Dis 5, e1271 (2014)","journal-title":"Cell Death Dis"},{"key":"314_CR62","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3892\/ijo.2015.3125","volume":"47","author":"A Garufi","year":"2015","unstructured":"A. Garufi, V. D'Orazi, A. Crispini, G. D'Orazi, Zn(II)-curc targets p53 in thyroid cancer cells. Int J Oncol 47, 1241\u20131248 (2015)","journal-title":"Int J Oncol"},{"key":"314_CR63","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1038\/sj.onc.1207396","volume":"23","author":"A Willis","year":"2004","unstructured":"A. Willis, E.J. Jung, T. Wakefield, X. Chen, Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23, 2330\u20132338 (2004)","journal-title":"Oncogene"},{"key":"314_CR64","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4161\/auto.6.7.12754","volume":"6","author":"G Filomeni","year":"2010","unstructured":"G. Filomeni, E. Desideri, S. Cardaci, G. Rotilio, M.R. Ciriolo, Under the ROS...thiol network is the principal suspect for autophagy commitment. Autophagy 6, 999\u20131005 (2010)","journal-title":"Autophagy"},{"key":"314_CR65","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1038\/onc.2014.458","volume":"34","author":"S Fulda","year":"2015","unstructured":"S. Fulda, D. Kogel, Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene 34, 5105\u20135113 (2015)","journal-title":"Oncogene"},{"key":"314_CR66","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1007\/s13277-013-1598-x","volume":"35","author":"G He","year":"2014","unstructured":"G. He, G. Chen, W. Chen, W. Zhang, J. Cao, Q. Ye, Lack of association of XRCC1 rs1799782 genetic polymorphism with risk of pancreatic cancer: a meta-analysis. Tumour Biol 35, 4545\u20134550 (2014)","journal-title":"Tumour Biol"},{"key":"314_CR67","doi-asserted-by":"crossref","first-page":"830260","DOI":"10.1155\/2011\/830260","volume":"2011","author":"H Rikiishi","year":"2011","unstructured":"H. Rikiishi, Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011, 830260 (2011)","journal-title":"J Biomed Biotechnol"},{"key":"314_CR68","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1073\/pnas.1204429109","volume":"109","author":"N Gammoh","year":"2012","unstructured":"N. Gammoh, D. Lam, C. Puente, I. Ganley, P.A. Marks, X. Jiang, Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A 109, 6561\u20136565 (2012)","journal-title":"Proc Natl Acad Sci U S A"},{"key":"314_CR69","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/15548627.2015.1023981","volume":"11","author":"J Zhang","year":"2015","unstructured":"J. Zhang, S. Ng, J. Wang, J. Zhou, S.H. Tan, N. Yang, Q. Lin, D. Xia, H.M. Shen, Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways. Autophagy 11, 629\u2013642 (2015)","journal-title":"Autophagy"},{"key":"314_CR70","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/B978-0-12-394387-3.00005-7","volume":"116","author":"GM Matthews","year":"2012","unstructured":"G.M. Matthews, A. Newbold, R.W. Johnstone, Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res 116, 165\u2013197 (2012)","journal-title":"Adv Cancer Res"},{"key":"314_CR71","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10495-014-0967-2","volume":"19","author":"S Mukhopadhyay","year":"2014","unstructured":"S. Mukhopadhyay, P.K. Panda, N. Sinha, D.N. Das, S.K. Bhutia, Autophagy and apoptosis: where do they meet? Apoptosis 19, 555\u2013566 (2014)","journal-title":"Apoptosis"},{"key":"314_CR72","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1038\/srep04241","volume":"4","author":"R Santarelli","year":"2014","unstructured":"R. Santarelli, R. Gonnella, G. Di Giovenale, L. Cuomo, A. Capobianchi, M. Granato, G. Gentile, A. Faggioni, M. Cirone, STAT3 activation by KSHV correlates with IL-10, IL-6 and IL-23 release and an autophagic block in dendritic cells. Sci Rep 4, 4241 (2014)","journal-title":"Sci Rep"},{"key":"314_CR73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075965","volume":"8","author":"M Granato","year":"2013","unstructured":"M. Granato, R. Santarelli, L.V. Lotti, L. Di Renzo, R. Gonnella, A. Garufi, P. Trivedi, L. Frati, G. D'Orazi, A. Faggioni, M. Cirone, JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. PLoS One 8, e75965 (2013)","journal-title":"PLoS One"},{"key":"314_CR74","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.biocel.2016.09.006","volume":"79","author":"M Granato","year":"2016","unstructured":"M. Granato, C. Rizzello, M.A. Romeo, S. Yadav, R. Santarelli, G. D'Orazi, A. Faggioni, M. Cirone, Concomitant reduction of c-Myc expression and PI3K\/AKT\/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma. Int J Biochem Cell Biol 79, 393\u2013400 (2016)","journal-title":"Int J Biochem Cell Biol"},{"key":"314_CR75","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13046-016-0417-9","volume":"35","author":"A Garufi","year":"2016","unstructured":"A. Garufi, G. Pistritto, M. Cirone, G. D'Orazi, Reactivation of mutant p53 by capsaicin, the major constituent of peppers. J Exp Clin Cancer Res 35, 136 (2016)","journal-title":"J Exp Clin Cancer Res"},{"key":"314_CR76","doi-asserted-by":"crossref","unstructured":"S.T. Nawrocki, J.S. Carew, M.S. Pino, R.A. Highshaw, R.H. Andtbacka, K. Dunner Jr., A. Pal, W.G. Bornmann, P.J. Chiao, P. Huang, H. Xiong, J.L. Abbruzzese, D.J. McConkey, Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 66, 3773\u20133781 (2006)","DOI":"10.1158\/0008-5472.CAN-05-2961"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-017-0314-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13402-017-0314-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-017-0314-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T03:02:50Z","timestamp":1568775770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13402-017-0314-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,3]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1007\/s13402-017-0314-z","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,3]]}}}